Role of proteins MRP8 (S100A8) and MRP14 (S100A9) in the development of critical condition in patients with pneumonia with A/H1N1 influenza

 Background. Today, the critical care medicine is actively developing, and rapid progress is closely related to the achievements of molecular biology, immunology, and pathological physiology. The study of the role of individual molecular structures in the realization of the reactions of innate and adaptive immunity, which underlie the pathogenesis of critical conditions, is an urgent scientific direction and is of interest.

Aims. To assess the contribution of the protein complex MRP-8/14 to the
development of systemic inflammation by determining its plasma  concentration in patients with pneumonia with influenza A/H1N1.

Materials and methods. 85 patients with pneumonia associated with influenza A/H1N1 were examined. Of these, 30 patients with severe pneumonia, 55 with non-severe pneumonia. The plasma concentration of the S100A8/A9 protein complex (MRP-8/14) was determined by flow cytometry on an analyzer (Beckman Coulter, USA).

Results. It was found that in patients with severe pneumonia with influenza A/H1N1, the concentration of MRP-8/14 increased in 1.9 times compared  with healthy. At the same time, in patients with severe pneumonia with influenza A/H1N1 with a fatal outcome, the concentration of MRP-8/14 increased in 2.1 times.

Conclusion. An increase in the level of MRP-8/14 in patients with severe pneumonia associated with influenza A/H1N1, on the one hand, reflects the severity of the course of systemic inflammation, on the other hand, the molecules MRP-8 and MRP-14, acting as damage-associated molecular patterns (DAMPs) stimulate a pro-inflammatory response and contribute to the development of critical state. Thereby, the protein complex MRP-8/14 can be considered as a potential point of application of pharmacological action in the intensive care of critical conditions. 

1. Gusev EYu, Chereshnev VA. Immunological and pathophysiological mechanisms of systemic inflammation. Medical Immunology/Meditsinskaya Immunologiya. 2012; 1–2. URL: https://cyberleninka.ru/article/n/immunologicheskie-ipatofiziologicheskie-mehanizmy-sistemnogo-vospaleniya. [date of access: 04/04/2021]. (In Russ.)

2. Gusev EYu, Zotova NV, Lazareva MA. Cytokine response and other distinctive features of critical phases of systemic inflammation in sepsis. Medical Immunology/Meditsinskaya Immunologiya. 2014; 2. URL: https://cyberleninka.ru / article / n / tsitokinovyy-otvet-i-drugie-otlichitelnyeosobennosti-kriticheskih-faz-sistemnogo-vospaleniya-prisepsise [date of access: 04/04/2021]. (In Russ.)

3. Nasonov EL, Aleksandrova EN, Novikov AA. Autoimmune rheumatic diseases – problems of immunopathology and personalized therapy. Vestnik RAMN. 2015; 70 (2):169–82. doi: 10.15690/vramn.v70i2.1310. (In Russ.)

4. Polushin YuS, Khrapov KN, Maiskaya MYu, Dikarev KV. Viral Pneumonia Influenza A (H1N1) Complicated by Acute Viral Respiratory Distress Syndrome. General Reanimatology. 2010;6 (3):15. doi.org/10.15360/1813-9779-2010-3-15. (In Russ.)

5. Khanova MYu, Grigoryev EV. Roles of PD-1 and PD–L1 receptors in the development of systemic inflammatory response and immunoadjuvant therapy. Patologiya krovoobrashcheniya i kardiokhirurgiya. Circulation Pathology and Cardiac Surgery. 2019; 23 (3):76–83. doi.org/10.21688/1681-3472-2019-3-76-83. (In Russ.)

6. Shcherbo SN. Development trends and technologies of modern laboratory medicine. Laboratornaya Meditsina. 2013; (12): 39–44 (In Russ.)

7. Ma Y, Fan D, Xu S, Deng J, Gao X, Guan S, et al. Calprotectin in spondyloarthritis: A systematic review and metaanalysis. Int Immunopharmacol. 2020; 88: 106948. doi: 10.1016/j.intimp.2020.106948

8. Simard JC, Cesaro A, Chapeton-Montes J, et al. S100A8 and S100A9 induce cytokine expression and regulate the NLRP3 inflammasome via ROS-dependent activation of NF-κB (1.). PLoS One. 2013; 8 (8):e72138. doi:10.1371/journal.pone.0072138

9. Foley Ch, MacDermott E, Killeen O. Myeloid-related proteins 8 and 14: potential biomarkers of disease activity of arthritis in children with trisomy 21. Rheumatology. 2015; 54 (2), doi.org/10.1093/rheumatology/keu521

10. Kerkhoff C, Nacken W, Benedyk M, Dagher MC, Sopalla C, Doussiere J. The arachidonic acid-binding protein S100A8/A9 promotes NADPH oxidase activation by interaction with p67phox and Rac-2. FASEB J. 2005; 19 (3):467–9. doi: 10.1096/fj.04-2377fje

11. Coutant R, Landais P, Rosilio M, Johnsen C, Lahlou N, Chatelain P, et al. Low dose linomide in type I juvenile diabetes of recent onset: a randomized placebo-controlled double-blind trial. Diabetologia. 1998; 41 (9): 1040-6. doi: 10.1007/s001250051028

12. Tsai SY, Segovia JA, Chang TH, Morris IR, Berton MT, Tessier PA, et al. DAMP molecule S100A9 acts as a molecular pattern to enhance inflammation during influenza A virus infection: role of DDX21- TRIF-TLR4-MyD88 pathway. PLoS Pathog. 2014; 10 (1):e1003848. doi: 10.1371/journal.ppat.1003848

13. Chereshnev VA, Gusev EYu. Immunologicheskie i patofiziologicheskie mekhanizmy sistemnogo vospaleniya [Immunological and pathophysiological mechanisms of systemic inflammation]. Meditsinskaya immunologiya/Medical Immunology. 2012; 14 (1–2): 9–20 (In Russ.)

14. Artemyeva OV, Gankovskaya LV. Inflammaging as the basis of age-associated diseases. Medical Immunology. 2020; 22 (3): 419–432. doi.org/10.15789/1563–0625-IAT-1938. (In Russ.)

15. Liu HY, Xiang HX, Xiang Y, Xu Z, Feng CM, Fei J, Fu L, Zhao H. The associations of serum S100A9 with the severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study. BMC Infect Dis. 2021; 21 (1): 327. doi: 10.1186/s12879-021-06020-y

16. Mahler M, Meroni PL, Infantino M, Buhler KA, Fritzler MJ. Circulating Calprotectin as a Biomarker of COVID-19 Severity. Expert Rev Clin Immunol. 2021; 13:1–13. doi: 10.1080/1744666X.2021.1905526

17. Udeh R, Advani S, de Guadiana Romualdo LG, DoljaGore X. Calprotectin, an Emerging Biomarker of Interest in COVID-19: A Systematic Review and Meta-Analysis. J Clin Med. 2021; 10 (4): 775. doi: 10.3390/jcm10040775

18. Al-Garawi A, Husain M, Ilieva D, Humbles AA, Kolbeck R, Stampfli MR, et al. Shifting of immune responsiveness to house dust mite by influenza A infection: genomic insights. J Immunol. 2012; 188 (2): 832–43. doi: 10.4049/jimmunol.1102349

19. Franchi L, Eigenbrod T, Muñoz-Planillo R, Nuñez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol. 2009; 10 (3): 241–7. doi: 10.1038/ni.1703

20. Safety of Remdesivir and Tocilizumab in COVID-19 Treatment. Safety and Risk of Pharmacotherapy. 2020; 8 (3): 160-162. doi.org/10.30895/2312-7821-2020-8-3-160-162. (In Russ.)

21. Nasonov EL. Coronavirus Disease 2019 (COVID-19): The Importance of IL-6 Inhibitors. Pul’monologiya. 2020; 30 (5): 629–644. doi: 10.18093/0869-0189-2020-30-5-629-644. (In Russ.)

22. Smirnov VS, Totolyan AA. Some possibilities of immunotherapy for coronavirus infection. Russian Journal of Infection and Immunity. 2020; 10 (3): 446–458. doi: 10.15789/2220–7619-SPO-1470 (In Russ.)

23. Stashkiv VI, Zamyatina KA, Shantarevich MYu, Nikitina IV, Kаrmаzаnovsky GG, Revishvili AS. CT findings in patients with COVID-19 pneumonia after treatment with tocilizumab: foreign literature review. Medical Visualization. 2020; 24 (2): 96–104. doi.org/10.24835/1607-0763-2020-2-96-97. (In Russ.)

24. Chen J, Chen R, Huang S, Zu B, Zhang S. Atezolizumab alleviates the immunosuppression induced by PD–L1-positive neutrophils and improves the survival of mice during sepsis. Mol Med Rep. 2021; 23 (2):1. doi: 10.3892/mmr.2020.11783

25. Bjork P, Bjork A, Vogl T, Stenstrom M, Liberg D, Olsson A, et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol. 2009; 7 (4):e97. doi:10.1371/journal.pbio.1000097

26. Bengtsson AA, Sturfelt G, Lood C, Rönnblom L, van Vollenhoven RF, Axelsson B, et al. Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebocontrolled, repeat-dose, dose-ranging study in p. Arthritis Rheumatol. 2012; 64 (5):1579–88. doi:10.1002/art. 33493

27. van Zoelen MA, Vogl T, Foell D, Van Veen SQ, van Till JW, Florquin S, et al. Expression and role of myeloid-related protein-14 in clinical and experimental sepsis. Am J Respir Crit Care Med. 2009; 180 (11): 1098–106. doi: 10.1164/rccm.200810-1552OC

28. Wang S, Song R, Wang Z, Jing Z, Wang S, Ma J. S100A8/A9 in Inflammation. Front Immunol. 2018; 9:1298. doi:10.3389/fimmu.2018.01298